1. Никифоров А.С., Коновалов А.Н., Гусев Е.И. Клиническая неврология. В 3 т. М.: Медицина, 2002.
2. Abdelrahman A, Al Suleimani Y. Four-week administration of nimesulide, a cyclooxygenase-2 inhibitor, improves endothelial dysfunction in the hindlimb vasculature of streptozotocin-induced diabetic rats. Аrch Pharm Res 2008; 31 (12): 1584–9.
3. Alotti N, Bod? E, Gombocz K et al. Management of postoperative inflammatory response and pain with nimesulide after cardiac surger. Orv Hetil 2003; 144 (48): 2353–7.
4. Beata R, Wojciech Н, Stanislaw S, Ryszard M. Influence of anti-inflammatory drugs on the proliferation of fibroblast derived from nasal polyps. Auris Nasus Larynx 2005; 32 (3): 225–9.
5. Bianchi M, Ferrario P, Balzarini P, Broggini M. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34 (4): 348–54.
6. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
7. Chou R et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147: 478–91.
8. Herrera J, Gonz?lez M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am J Ther 2003; 10 (6): 468–72.
9. Ilic K, Sefik-Bukilica M, Jankovic S, Vujasinovic-Stupar N. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo 2009; 61 (1): 27–33.
10. Koseoglu B, Ozturk S, Kocak H. The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. Yonsei Med J 2008; 49 (5): 742–7. Eur Ann Allergy Clin Immunol 2006; 38 (6): 182–517.
11. Omololu B, Alonge T, Ogunlade S, Aduroja O. Double blind clinical trial comparing the safety and efficacy of nimesulide (100 mg) and diclofenac in osteoarthrosis of the hip and knee joints. West Afr J Med 2005; 24 (2): 128–33.
12. Palma-Carlos A, Medina M, Palma-Carlos M. Skin tests in NSAIDS hypersensitivity. Eur Ann Allergy Clin Immunol 2006; 38 (6): 182–5.
13. Pilotto A, Seripa D, Franceschi M et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: Role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133: 465–71.
14. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
15. Rabenda V, Burlet N, Belaiche J. Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care. Osteoarthritis Cartilage 2006; 14 (7): 625–30.
16. Rainsford K. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (Oxford) 1999; 38 (Suppl. 1): 4–10.
17. Rainsford K. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology 2006; 14 (3–4): 120–37.
18. Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem 2008; 15 (3): 278–83.
19. Topol E. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351 (17): 1707–9.
20. Trnavsky K. Nimesulide: a lower risk treatment in rheumatic diseases. Vnitr Lek 2004; 50 (2): 157–62.
21. van Tulder M, Becker A, Bekkering T et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15 (Suppl. 2): S169–91.